MP Healthcare Venture Management
Home About Us Portfolio News Contact
HomeAbout UsPortfolioNewsContact
MP Healthcare Venture Management
Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Studay for Acute Kidney Injury.
Brennan CaruthersJuly 7, 2015
Facebook0 Twitter LinkedIn0 Reddit 0 Likes
Previous

miRagen Therapeutics Secures $41 million Series C Financing to Advance Two MicroRNA Programs into Clinical Trials.

Brennan CaruthersNovember 10, 2015
Next

Thrasos Secures $21 Million to Complete Phase 2 Study of THR-184 in the Prevention of Acute Kidney Injury and Expand the Company's Renal Portfolio.

Brennan CaruthersMarch 31, 2015

© 2010-2019 MP Healthcare Venture Management, Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

About UsPortfolioNews Contact